Blanquicett Carmelo, Roman Jesse, Hart C Michael
Department of Medicine, Emory University and Atlanta Veterans Affairs Medical Centers, Atlanta, GA 30033.
Cancer Ther. 2008;6(A):25-34.
The PPAR-gamma (PPAR-γ) activating thiazolidinedione (TZD) medications are a class of drugs used to improve lipid and glucose metabolism in type-2 diabetes. In addition to their known insulin sensitization action, these drugs have been shown to suppress tumor development in several in vitro and in vivo models. Among the proposed mechanisms for the anti-tumor effects of TZDs, apoptosis induction, cell cycle arrest, and differentiation have been extensively reported. Interestingly, some of the observed anti-tumor effects are independent of PPAR-γ activation. The following review will discuss studies employing TZDs as anti-cancer therapies for the most common types of cancers including, lung, breast, and colon and will explore the principal PPAR-γ-dependent and -independent mechanisms by which TZDs exert their anti-tumor effects.
激活过氧化物酶体增殖物激活受体γ(PPAR-γ)的噻唑烷二酮(TZD)类药物是一类用于改善2型糖尿病患者脂质和葡萄糖代谢的药物。除了已知的胰岛素增敏作用外,这些药物在多种体外和体内模型中均显示出抑制肿瘤发展的作用。在提出的TZD类药物抗肿瘤作用机制中,诱导凋亡、细胞周期阻滞和分化已被广泛报道。有趣的是,一些观察到的抗肿瘤作用独立于PPAR-γ激活。以下综述将讨论使用TZD类药物作为肺癌、乳腺癌和结肠癌等最常见癌症的抗癌疗法的研究,并探讨TZD类药物发挥抗肿瘤作用的主要PPAR-γ依赖性和非依赖性机制。